YING YUAN to Humans
This is a "connection" page, showing publications YING YUAN has written about Humans.
Connection Strength
0.670
-
Bayesian optimal phase II designs with dual-criterion decision making. Pharm Stat. 2023 Jul-Aug; 22(4):605-618.
Score: 0.018
-
Commentary on "Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies". Stat Med. 2022 Nov 30; 41(27):5484-5490.
Score: 0.017
-
A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint. Pharm Stat. 2023 01; 22(1):34-44.
Score: 0.017
-
A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints. Biometrics. 2023 06; 79(2):1459-1471.
Score: 0.017
-
TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med. 2022 05 20; 41(11):1918-1931.
Score: 0.016
-
Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer. JCO Precis Oncol. 2021; 5.
Score: 0.016
-
Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials. Contemp Clin Trials. 2021 08; 107:106460.
Score: 0.016
-
Incorporating historical information to improve phase I clinical trials. Pharm Stat. 2021 11; 20(6):1017-1034.
Score: 0.016
-
Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemp Clin Trials. 2021 05; 104:106338.
Score: 0.015
-
BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials. JCO Clin Cancer Inform. 2021 01; 5:91-101.
Score: 0.015
-
Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics. 2020 10 01; 21(4):807-824.
Score: 0.015
-
TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. J Natl Cancer Inst. 2020 01 01; 112(1):38-45.
Score: 0.014
-
A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Stat Med. 2019 12 10; 38(28):5299-5316.
Score: 0.014
-
An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics. 2020 03; 76(1):304-315.
Score: 0.014
-
On the relative efficiency of model-assisted designs: a conditional approach. J Biopharm Stat. 2019; 29(4):648-662.
Score: 0.014
-
Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res. 2018 10 15; 24(20):4921-4930.
Score: 0.013
-
Comparative review of novel model-assisted designs for phase I clinical trials. Stat Med. 2018 06 30; 37(14):2208-2222.
Score: 0.013
-
BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Stat Med. 2017 Sep 20; 36(21):3302-3314.
Score: 0.012
-
A functional variant at the miRNA binding site in E2F1 gene is associated with risk and tumor HPV16 status of oropharynx squamous cell carcinoma. Mol Carcinog. 2017 03; 56(3):1100-1106.
Score: 0.011
-
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clin Cancer Res. 2016 Sep 01; 22(17):4291-301.
Score: 0.011
-
Utility-based designs for randomized comparative trials with categorical outcomes. Stat Med. 2016 10 30; 35(24):4285-4305.
Score: 0.011
-
MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Stat Med. 2016 09 30; 35(22):3892-906.
Score: 0.011
-
Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance. Stat Med. 2015 Jun 15; 34(13):2104-15.
Score: 0.010
-
A direct method to evaluate the time-dependent predictive accuracy for biomarkers. Biometrics. 2015 Jun; 71(2):439-49.
Score: 0.010
-
Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Stat Med. 2015 May 10; 34(10):1681-94.
Score: 0.010
-
Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clin Trials. 2014 06; 11(3):319-327.
Score: 0.010
-
Bayesian latent-class mixed-effect hybrid models for dyadic longitudinal data with non-ignorable dropouts. Biometrics. 2013 Dec; 69(4):914-24.
Score: 0.009
-
Robust mediation analysis based on median regression. Psychol Methods. 2014 Mar; 19(1):1-20.
Score: 0.009
-
A shrinkage method for testing the Hardy-Weinberg equilibrium in case-control studies. Genet Epidemiol. 2013 Nov; 37(7):743-50.
Score: 0.009
-
Dose-response curve estimation: a semiparametric mixture approach. Biometrics. 2011 Dec; 67(4):1543-54.
Score: 0.008
-
A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med. 2011 May 20; 30(11):1218-29.
Score: 0.008
-
On the usefulness of outcome-adaptive randomization. J Clin Oncol. 2011 May 01; 29(13):e390-2; author reply e393.
Score: 0.008
-
Bayesian hybrid dose-finding design in phase I oncology clinical trials. Stat Med. 2011 Jul 30; 30(17):2098-108.
Score: 0.008
-
Bayesian mediation analysis. Psychol Methods. 2009 Dec; 14(4):301-22.
Score: 0.007
-
Sequential continual reassessment method for two-dimensional dose finding. Stat Med. 2008 Nov 29; 27(27):5664-78.
Score: 0.007
-
A latent contingency table approach to dose finding for combinations of two agents. Biometrics. 2009 Sep; 65(3):866-75.
Score: 0.006
-
Comments on 'An exploratory test for an excess of significant findings' by JPA loannidis and TA Trikalinos. Clin Trials. 2007; 4(3):254-5; discussion 256-7.
Score: 0.006
-
CLO24-088: Efficacy of Fruquintinib in Less Heavily Pretreated Patients (Pts) With Metastatic Colorectal Cancer (mCRC): Profile-Matched Data From FRESCO and FRESCO-2. J Natl Compr Canc Netw. 2024 Apr 05; 22(2.5).
Score: 0.005
-
A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biom J. 2024 Mar; 66(2):e2300122.
Score: 0.005
-
The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab. J Neurooncol. 2024 Mar; 167(1):181-188.
Score: 0.005
-
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer Res Commun. 2024 02 12; 4(2):378-387.
Score: 0.005
-
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2).
Score: 0.005
-
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023 Dec; 24(12):1387-1398.
Score: 0.005
-
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.
Score: 0.005
-
Novel Clinical Trial Designs with Dose Optimization to Improve Long-term Outcomes. Clin Cancer Res. 2023 11 14; 29(22):4549-4554.
Score: 0.005
-
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. J Immunother Cancer. 2023 08; 11(8).
Score: 0.005
-
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734.
Score: 0.004
-
Inhibition of the CD47-SIRPa axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022; 13:1027235.
Score: 0.004
-
AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials. Pharm Stat. 2023 03; 22(2):300-311.
Score: 0.004
-
Changes in Apparent Diffusion Coefficient (ADC) in Serial Weekly MRI during Radiotherapy in Patients with Head and Neck Cancer: Results from the PREDICT-HN Study. Curr Oncol. 2022 08 31; 29(9):6303-6313.
Score: 0.004
-
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420.
Score: 0.004
-
Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol. 2022 02; 6:e2100267.
Score: 0.004
-
Healthy Moves to Improve Lifestyle Behaviors of Cancer Survivors and Their Spouses: Feasibility and Preliminary Results of Intervention Efficacy. Nutrients. 2021 Dec 14; 13(12).
Score: 0.004
-
Mobile Text Messaging for Tobacco Risk Communication Among Young Adult Community College Students: Randomized Trial of Project Debunk. JMIR Mhealth Uhealth. 2021 11 24; 9(11):e25618.
Score: 0.004
-
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
Score: 0.004
-
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67.
Score: 0.004
-
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
Score: 0.004
-
Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. 2021 04; 161(1):104-112.
Score: 0.004
-
Endometrial biomarkers in premenopausal women with obesity: an at-risk cohort. Am J Obstet Gynecol. 2021 03; 224(3):278.e1-278.e14.
Score: 0.004
-
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 02; 224(2):191.e1-191.e15.
Score: 0.004
-
Sponsor-involved statistical analyses in Phase III cancer clinical trials. Int J Cancer. 2020 12 15; 147(12):3579-3581.
Score: 0.004
-
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
Score: 0.004
-
Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. Clin Cancer Res. 2019 11 15; 25(22):6801-6814.
Score: 0.003
-
Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. Clin Trials. 2019 12; 16(6):645-656.
Score: 0.003
-
Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer. 2019 05; 112:83-93.
Score: 0.003
-
Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. BMC Cancer. 2018 Sep 19; 18(1):903.
Score: 0.003
-
Hispidulin induces ER stress-mediated apoptosis in human hepatocellular carcinoma cells in vitro and in vivo by activating AMPK signaling pathway. Acta Pharmacol Sin. 2019 May; 40(5):666-676.
Score: 0.003
-
Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prev Res (Phila). 2018 08; 11(8):477-490.
Score: 0.003
-
Hispidulin inhibits hepatocellular carcinoma growth and metastasis through AMPK and ERK signaling mediated activation of PPAR?. Biomed Pharmacother. 2018 Jul; 103:272-283.
Score: 0.003
-
Accuracy, Safety, and Reliability of Novel Phase I Trial Designs. Clin Cancer Res. 2018 09 15; 24(18):4357-4364.
Score: 0.003
-
Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2018 01 10; 20(1):113-122.
Score: 0.003
-
Using 18F-fluorodeoxyglucose positron emission tomography/computed tomography to estimate the length of gross tumor and involvement of lymph nodes in esophagogastric junction carcinoma. J Cancer Res Ther. 2018; 14(4):896-901.
Score: 0.003
-
Thrombocytosis as a prognostic factor in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Dec; 166(3):819-832.
Score: 0.003
-
Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res. 2017 07 15; 77(14):3894-3907.
Score: 0.003
-
Cancer screening behaviors and risk perceptions among family members of colorectal cancer patients with unexplained mismatch repair deficiency. Fam Cancer. 2017 04; 16(2):231-237.
Score: 0.003
-
Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Clin Cancer Res. 2017 Aug 01; 23(15):4473-4481.
Score: 0.003
-
Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancer. BMC Bioinformatics. 2016 May 26; 17(1):222.
Score: 0.003
-
Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget. 2015 Nov 24; 6(37):39865-76.
Score: 0.003
-
Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol. 2016 Feb; 126(3):527-33.
Score: 0.003
-
Venous thromboembolism (VTE) and glioblastoma. J Neurooncol. 2015 Aug; 124(1):87-94.
Score: 0.003
-
FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells. Cancer Res. 2015 Jun 01; 75(11):2337-48.
Score: 0.003
-
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol. 2015 Apr; 129(4):585-96.
Score: 0.003
-
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro Oncol. 2015 Mar; 17(3):440-7.
Score: 0.002
-
The continual reassessment method for multiple toxicity grades: a bayesian model selection approach. PLoS One. 2014; 9(5):e98147.
Score: 0.002
-
Assessment of a quantitative metric for 4D CT artifact evaluation by observer consensus. J Appl Clin Med Phys. 2014 May 08; 15(3):4718.
Score: 0.002
-
Pregnancy and glial brain tumors. Neuro Oncol. 2014 Sep; 16(9):1289-94.
Score: 0.002
-
Evaluation of image registration spatial accuracy using a Bayesian hierarchical model. Biometrics. 2014 Jun; 70(2):366-77.
Score: 0.002
-
A high Notch pathway activation predicts response to ? secretase inhibitors in proneural subtype of glioma tumor-initiating cells. Stem Cells. 2014 Jan; 32(1):301-12.
Score: 0.002
-
Clinical and prognostic features of adult patients with gangliogliomas. Neuro Oncol. 2014 Mar; 16(3):409-13.
Score: 0.002
-
Efficacy trial of an Internet-based intervention for cancer-related female sexual dysfunction. J Natl Compr Canc Netw. 2013 Nov; 11(11):1389-97.
Score: 0.002
-
Adherence to preventive exercises and self-reported swallowing outcomes in post-radiation head and neck cancer patients. Head Neck. 2013 Dec; 35(12):1707-12.
Score: 0.002
-
Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol. 2013 Sep; 114(2):229-35.
Score: 0.002
-
DeMix: deconvolution for mixed cancer transcriptomes using raw measured data. Bioinformatics. 2013 Aug 01; 29(15):1865-71.
Score: 0.002
-
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer. 2013 Aug 01; 119(15):2747-53.
Score: 0.002
-
Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells. Cancer Res. 2013 May 15; 73(10):3062-74.
Score: 0.002
-
Bayesian adaptive phase II screening design for combination trials. Clin Trials. 2013; 10(3):353-62.
Score: 0.002
-
Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets. PLoS One. 2012; 7(9):e45894.
Score: 0.002
-
Associations among speech, eating, and body image concerns for surgical patients with head and neck cancer. Head Neck. 2013 Mar; 35(3):354-60.
Score: 0.002
-
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4123-8.
Score: 0.002
-
[Influences of diagnostic modes on an early diagnosis of colorectal cancer]. Zhonghua Yi Xue Za Zhi. 2011 Nov 08; 91(41):2886-90.
Score: 0.002
-
Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res. 2012 Jan 01; 18(1):184-95.
Score: 0.002
-
A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. Cancer. 2012 Jan 15; 118(2):500-9.
Score: 0.002
-
The nature and extent of body image concerns among surgically treated patients with head and neck cancer. Psychooncology. 2012 Aug; 21(8):836-44.
Score: 0.002
-
Feasibility of an expressive-disclosure group intervention for post-treatment colorectal cancer patients: results of the Healthy Expressions study. Cancer. 2011 Nov 01; 117(21):4993-5002.
Score: 0.002
-
Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011 Sep 01; 117(17):3900-7.
Score: 0.002
-
Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity. Lifetime Data Anal. 2011 Jan; 17(1):156-74.
Score: 0.002
-
Do male lymphoma survivors have impaired sexual function? J Clin Oncol. 2009 Dec 10; 27(35):6019-26.
Score: 0.002
-
Distributions of angiogenesis and lymphangiogenesis in gastrointestinal intramucosal tumors. Ann Surg Oncol. 2008 Apr; 15(4):1117-23.
Score: 0.002
-
Dental caries and dietary patterns in low-income African American children. Pediatr Dent. 2007 Nov-Dec; 29(6):457-64.
Score: 0.002
-
Reversal MDR in breast carcinoma cells by transfection of ribozyme designed according the secondary structure of mdr1 mRNA. Chin J Physiol. 2006 Apr 30; 49(2):96-103.
Score: 0.001
-
The finished DNA sequence of human chromosome 12. Nature. 2006 03 16; 440(7082):346-51.
Score: 0.001
-
Dietary patterns related to caries in a low-income adult population. Caries Res. 2006; 40(6):473-80.
Score: 0.001